论文部分内容阅读
微量白蛋白尿可早期预测糖尿病肾病(DN)和早期(premature)心血管疾病。研究者考察了血管紧张素受体阻滞剂(ARB)治疗是否会延缓、预防尿白蛋白正常的2型糖尿病(T2DM)患者的微量白蛋白尿的出现。该项随机、双盲、多中心对照试验共纳入4447例T2DM患者并进行分组,分别予以奥美沙坦(40mg,qd)或安慰剂,持续中位时间为3.2年。并按需加用降压药物[除了血管紧张素转换酶抑制剂(ACEI)或ARBs],以将血压降至130/80mm Hg以下。主要转归是首次出现微量白蛋白尿的时间。次级终点为发生肾脏或心血管事件的时间。
Microalbuminuria predicts early diabetic nephropathy (DN) and premature cardiovascular disease. The researchers examined whether angiotensin receptor blocker (ARB) treatment would delay the onset of microalbuminuria in patients with type 2 diabetes mellitus (T2DM). A total of 4447 patients with T2DM were enrolled in this randomized, double-blind, multicenter, controlled trial and were assigned to either olmesartan (40 mg, qd) or placebo for a median duration of 3.2 years. Blood pressure was reduced to below 130/80 mm Hg with antihypertensive drugs [except angiotensin converting enzyme inhibitors (ACEIs) or ARBs] as needed. The primary outcome is the time when microalbuminuria first appeared. The secondary endpoint is the time at which a kidney or cardiovascular event occurred.